Help
Subscribe


All of GastroHep is now free access! - Click here to register Read For FREE - Our full range of review articles
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy Profile of Guido Tytgat Profile of Pete Peterson Profile of Peter Cotton Profile of Roy Pounder

Home

News  
Journals
Review Articles
Slide Atlas
Video Clips
Online Books
Advanced Digestive Endoscopy
Classical Cases
Conference Diary
PubMed
International GH Links
USA GH Links
National GH Links
National GI Societies
Other Useful Links




Emails on Gastroenterology and Hepatology
the National AIDS Treatment Advocacy Project
Visit the gastroenterology section of the EUMS

News

Treatment of Hepatitis B in chronic kidney disease patients

January's issue of the Alimentary Pharmacology & Therapeutics examines the use of nucleos(t)ide analogues in patients with chronic hepatitis B virus infection and chronic kidney disease.

News image

The treatment of chronic hepatitis B in patients with chronic kidney disease (CKD) is based on nucleoside (lamivudine, telbivudine, entecavir) or nucleotide (adefovir, tenofovir) analogues (NAs), but it may be complex and the information is scarce.

Entecavir and tenofovir represent the currently recommended first-line NAs for NA-naive chronic hepatitis B patients, while tenofovir is the NA of choice for chronic hepatitis B patients with resistance to nucleosides.

Dr Papatheodoridis and colleagues from Greece reviewed the efficacy and safety of NAs in adult chronic hepatitis B patients with chronic kidney disease and to provide reasonable recommendations for their optimal management.

The team performed a literature search in PubMed/Medline and manual search of relevant articles, reviews and book chapters.

Psychiatric drug dispensings were more common among female IBD patients
Alimentary Pharmacology & Therapeutics

NAs are cleared by kidneys and their dosage should be adjusted in patients with creatinine clearance <50 mL/min.

The team report concerns about nephrotoxic potential of the nucleotides, particularly adefovir, while improvements of creatinine clearance have been reported under telbivudine.

The researchers noted that most existing data in chronic hepatitis B patients with CKD are for lamivudine and, less frequently, for other NAs, mostly entecavir.

Besides chronic hepatitis B, NA should be used in case of immunosuppressive therapy in any HBsAg-positive patient with CKD including renal transplant (RT) recipients, and in anti-HBs-positive recipients of kidney grafts from HBsAg-positive donors.

Dr Papatheodoridis' team comments, "Chronic hepatitis B patients with chronic kidney disease receiving nucleoside analogues should be followed carefully for treatment efficacy and renal safety."

"Despite the absence of strong data, entecavir and telbivudine seem to be the preferred options for nucleoside analogue-naive chronic hepatitis B patients with chronic kidney disease, depending on viraemia and severity of renal dysfunction."

"More studies are certainly needed in this setting."

Aliment Pharmacol Ther 2014: 39(1): 35-46
11 December 2013

Go to top of page Email this page Email this page to a colleague

 02 September 2014

Advanced search
 02 September 2014 
Eosinophilic esophagitis in adults
 02 September 2014 
SSRIs and depression in Hep C
 02 September 2014 
Bariatric surgery for obesity
 01 September 2014 
Genetic variants in alcoholic liver disease
 01 September 2014 
Fecal hemoglobin and colorectal cancer screening
 01 September 2014 
Risks with anti-TNF in pediatric IBD
 29 August 2014 
NSAID-induced small intestinal injury and diaphragm disease
 29 August 2014 
Symptom evaluation in functional dyspepsia
 29 August 2014 
Gluten-free diet for asymptomatic celiac disease
 28 August 2014 
Detection of gastroesophageal reflux symptoms
 28 August 2014 
Colorectal-cancer mortality after adenoma removal
 28 August 2014 
Predictoris of C. diff in out-patients
 27 August 2014 
Endoscopy outcomes in community hospital vs tertiary academic centers
 27 August 2014 
UV exposure and IBD hospitalizations
 27 August 2014 
Hepatocellular carcinoma screening in liver disease
 26 August 2014 
NAFLD and gastroesophageal reflux symptoms
 26 August 2014 
Adalimumab-treated patients with ulcerative colitis
 26 August 2014 
Wound healing after abdominoperineal resection
 25 August 2014 
Surgical management of rectourethral fistulas
 25 August 2014 
Biomarker analysis in biopsies for ulcerative colitis
 25 August 2014 
Ileocolic resection in Crohn's disease
 22 August 2014 
Outlier identification in colorectal surgery
 22 August 2014 
Endoscopic submucosal dissection for squamous esophageal cancer
 22 August 2014 
Adherence to Rome criteria in functional dyspepsia trials
 21 August 2014 
Screening for Barrett’s esophagus
 21 August 2014 
Colorectal cancer mortality in Brazil
 21 August 2014 
Eosinophilic esophagitis
 20 August 2014 
Rectal surgery mortality
 20 August 2014 
Chemotherapy-induced gastrointestinal mucositis
 20 August 2014 
Stool methylated DNA markers and colorectal cancer resection
 19 August 2014 
Recurrent C. difficile infection in out-patients
 19 August 2014 
Racial disparities and colon cancer
 19 August 2014 
Variability of colonoscopy preparation instructions
 18 August 2014 
The evolution of urban C. difficile
 18 August 2014 
Metabolomic analysis in IBD
 18 August 2014 
Enhanced T-cell response in acute-on-chronic Hep B
 15 August 2014 
Abdominal pain in IBS
 15 August 2014 
Gene expression biomarker in ulcerative colitis
 15 August 2014 
Population-based fecal immunochemical test screening
 14 August 2014 
Transnasal vs transoral endoscopy
 14 August 2014 
Radiation exposure in gastroenterology
 14 August 2014 
Dietary fibre and diverticular disease
 13 August 2014 
Fecal immunochemical test screening
 13 August 2014 
Adherence to Rome criteria in functional dyspepsia
 13 August 2014 
Flexible sigmoidoscopy screening
 12 August 2014 
Eosinophilic esophagitis and celiac disease
 12 August 2014 
Management of Lynch syndrome
 12 August 2014 
Risk of cancer under immunosuppressive therapy in IBD
 11 August 2014 
Gut microbiota in chemotherapy-induced GI mucositis
 11 August 2014 
Risk of GI bleeds with anticoagulants
 11 August 2014 
Social media in health-care
 08 August 2014 
Endoscopy nurse-administered propofol sedation performance
 08 August 2014 
Therapy for biliary tract cancer
 08 August 2014 
Surgeon volume and esophagectomy survival
 07 August 2014 
Global consensus on perianal fistulizing Crohn's disease
 07 August 2014 
Smoking cessation and age of onset of ulcerative colitis
 07 August 2014 
Colonoscopy length and training duration
 06 August 2014 
Hepatitis C virus infection in the United States
 06 August 2014 
Pediatric to adult IBD care
 06 August 2014 
Biomarker of disease activity in IBD

Blackwell Publishing


GastroHep.com is a Blackwell Publishing registered trademark
© 2014 Wiley-Blackwell and GastroHep.com and contributors
Privacy Statement
Disclaimer
About Us